Damon Reed, MD

Where You Are:
Damon Reed, MD

Assistant Member

Office  (813) 745-4292

Education And Training
  • Fellow, St. Jude Children's Hospital, 2008 - Pediatric Hematology Oncology
  • Intern & Resident, Boston Medical Center, 2005 - Pediatrics
  • Intern & Resident, Children's Hospital Boston, 2005 - Medicine
  • MD, Case Western University School of Medicine, 2002


Dr. Reed’s research interest focuses on the prediction of conventional chemotherapy efficacy in non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) using ex vivo assays and xenograft models. The research of Dr. Reed’s group is conducted in Dr. Altiok’s laboratory in close collaboration and is focused on biomarker discovery and validation in order to predict clinical benefit in NRSTS. The work has focused on creating a panel of representative NRSTS xenografts from fresh, untreated human sarcomas and serially transplanting them through generations in immunodeficient mice.  Furthermore, fresh human tissue is tested ex vivo in the presence of clinically relevant chemotherapeutic agents and molecular pathways of DNA damage, cell cycle arrest and apoptosis; analysis includes, but is not limited to, PARP cleavage, gammaH2AX, and Rb.  Currently, through support from the Sarcoma Foundation of America, the xenografts are being treated in vivo with agents or combinations with correlative ex vivo results.

  • Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):371-382. Pubmedid: 23477833.
  • Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ, Altiok S. Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas. PLoS One. 2013;8(3):e57523. Pubmedid: 23520471.
  • Fu W, Sharma SS, Ma L, Chu B, Bui MM, Reed D, Pledger WJ. Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. Cell Death Dis. 2013;4:e566. Pubmedid: 23538447.
  • Vohra NA, Turaga KK, Gonzalez RJ, Conley A, Reed D, Bui MM, Cheong D, Letson DG, Zager JS. The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperthermia. 2013;29(1):1-7. Pubmedid: 23205633.
  • Han D, Zager JS, Han G, Marzban SS, Puleo CA, Sarnaik AA, Reed D, Messina JL, Sondak VK. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol. 2012 Nov;19(12):3888-3895. Pubmedid: 22864798.
  • Koohbanani B, Han G, Reed D, Zhao Q, Yi D, Henderson-Jackson E, Bui MM. Ethnicity and age disparities in Ewing sarcoma outcome. Fetal Pediatr Pathol. 2012 Oct. Pubmedid: 23043418.
  • Coccia PF, Altman J, Bhatia S, Borinstein SC, Flynn J, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Pappo AS, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack BJ, Sundar H, Shead DA. Adolescent and young adult oncology. J Natl Compr Canc Netw. 2012 Sep;10(9):1112-1150. Pubmedid: 22956810.
  • Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells. Mol Cancer Ther. 2012 Jan;11(1):174-182. Pubmedid: 22084170.
  • Reed D, Altiok S. Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine. Cancer Control. 2011 Jul;18(3):188-195. Pubmedid: 21666581.
  • Bui MM, Han G, Acs G, Reed D, Gonzalez RJ, Pasha TL, Zhang PJ. Connexin 43 is a potential prognostic biomarker for ewing sarcoma/primitive neuroectodermal tumor. Sarcoma. 2011;2011:971050. Pubmedid: 21647307. Pmcid: PMC3103998.
  • Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem. 2010 Apr;285(14):10786-10796. Pubmedid: 20080970. Pmcid: PMC2856285.
  • Finelli DA, Reed DR. Flip angle dependence of experimentally determined T1sat and apparent magnetization transfer rate constants. J Magn Reson Imaging. 1998 May;8(3):548-553. Pubmedid: 9626867.
TOOLS:   Font Size